HEPACAM and amyotrophic lateral sclerosis: Although qualitative, the relative increase in tissue immunoreactivity seen for GFAP, HEPACAM, MSN, and TPP1 in the ALS/FTD case likely reflects changes in the abundance of astrocytes and microglia measured by mass spectrometry and confirmed by Western blotting.